Skip to main content
Journal cover image

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.

Publication ,  Journal Article
Jamnagerwalla, J; Howard, LE; Vidal, AC; Moreira, DM; Castro-Santamaria, R; Andriole, GL; Freedland, SJ
Published in: The Journal of urology
September 2016

Despite routine use of phosphodiesterase type 5 inhibitor to treat erectile dysfunction the role in prostate cancer chemoprevention remains unclear. Only a few studies have explored the link between phosphodiesterase type 5 inhibitor use and prostate cancer. We tested the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial.REDUCE was a 4-year multicenter study testing the effect of daily dutasteride on prostate cancer risk in men with prostate specific antigen 2.5 to 10.0 ng/ml and negative biopsy who underwent study mandated biopsies at 2 and 4 years. The association of phosphodiesterase type 5 inhibitor with overall prostate cancer risk and disease grade (Gleason 2-6 and 7-10) was examined using adjusted logistic and multinomial regression analysis. Secondary analysis was performed to explore the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in North American men, given the significantly higher use of phosphodiesterase type 5 inhibitor in these subjects.Phosphodiesterase type 5 inhibitor was not associated with prostate cancer diagnosis (OR 0.90, 95% CI 0.68-1.20, p = 0.476), low grade disease (OR 0.93, 95% CI 0.67-1.27, p = 0.632) or high grade disease (OR 0.85, 95% CI 0.51-1.39, p = 0.508). An inverse trend was seen between phosphodiesterase type 5 inhibitor and prostate cancer diagnosis in North American men but this was not statistically significant (OR 0.67, 95% CI 0.42-1.07, p = 0.091).Phosphodiesterase type 5 inhibitor use was not associated with decreased prostate cancer diagnoses on post-hoc analysis of REDUCE. In North American men, who had much higher baseline use of phosphodiesterase type 5 inhibitor, this treatment was associated with an inverse trend of prostate cancer diagnosis that approached but did not reach statistical significance.

Duke Scholars

Published In

The Journal of urology

DOI

EISSN

1527-3792

ISSN

0022-5347

Publication Date

September 2016

Volume

196

Issue

3

Start / End Page

715 / 720

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Humans
  • Erectile Dysfunction
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jamnagerwalla, J., Howard, L. E., Vidal, A. C., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., & Freedland, S. J. (2016). The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. The Journal of Urology, 196(3), 715–720. https://doi.org/10.1016/j.juro.2016.03.172
Jamnagerwalla, Juzar, Lauren E. Howard, Adriana C. Vidal, Daniel M. Moreira, Ramiro Castro-Santamaria, Gerald L. Andriole, and Stephen J. Freedland. “The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.The Journal of Urology 196, no. 3 (September 2016): 715–20. https://doi.org/10.1016/j.juro.2016.03.172.
Jamnagerwalla J, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, et al. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. The Journal of urology. 2016 Sep;196(3):715–20.
Jamnagerwalla, Juzar, et al. “The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.The Journal of Urology, vol. 196, no. 3, Sept. 2016, pp. 715–20. Epmc, doi:10.1016/j.juro.2016.03.172.
Jamnagerwalla J, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. The Journal of urology. 2016 Sep;196(3):715–720.
Journal cover image

Published In

The Journal of urology

DOI

EISSN

1527-3792

ISSN

0022-5347

Publication Date

September 2016

Volume

196

Issue

3

Start / End Page

715 / 720

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Humans
  • Erectile Dysfunction